Company intelligence / Profile preview

Avidia

Mountain View, California, United Statesavidiabank.com ↗

Ownership: Private
Development stage: Other

Overview

Avidia developed a new class of human therapeutic proteins called Avimers™, with its lead candidate being an IL‑6 inhibitor for inflammation and autoimmune diseases. The lead program was in Phase 1 clinical trials at the time of acquisition by Amgen. The Avimer platform allowed engineering modular protein therapeutics targeting multiple disease areas with potential advantages in activity, safety profile, and manufacturing.[1][2]

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Protein therapeutics (Avimer™ proteins)
Industry: Biotech

Beyond the preview

Go deeper on Avidia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avidia.

Explore the full profile